FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								

37 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940.

											j									
1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					٦١١	[COLL]								X	Directo	r		10% Ov	/ner	
(Last)	(F	irst)	(Middle)		Ĺ	[3322]									Officer below)	(give title		Other (s below)	pecify	
C/O COLLEGIUM PHARMACEUTICAL, INC.						3. Date of Earliest Transaction (Month/Day/Year) 04/25/2019														
100 TECHNOLOGY CENTER DRIVE																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) STOUGHTON MA 02072													X Form filed by One Reporting Person							
													-	Form f Persor	n One Repo	rting				
(City)	(S	itate)	(Zip)																	
		Tab	le I - Nor	n-Deriv	/ative	Se	curitie	s Acc	quired, [Disp	osed c	of, or Be	enefici	ally	Owned					
Date					saction		2A. Deemed Execution Date,					ities Acquired (A) or d Of (D) (Instr. 3, 4 and			5. Amount of Securities				7. Nature of Indirect	
					th/Day/Year)		if any (Month/Day/Year		Code (Instr.				311. 3, 4	uiu	Benefici	Beneficially Owned Following		r Indirect	Beneficial Ownership	
										v	Amount	(A) or (D)		e	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock 04/25					5/2019	/2019		A		4,707	707 ⁽¹⁾ A		0	6,960			D			
		7	able II -	Deriva	tive S	Seci	urities	Acqı	uired, Di	spo	sed of	, or Ben	eficia	lly C	Owned					
									, options											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transactio Code (Inst 8)		n of I		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		S (I	. Price of lerivative lecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					O- d-				Date		Expiration Date	Tial -	Amour or Number of	per						
Stock				-	Code	V	(A)	(D)	Exercisable	10	ale	Title	Share	+					-	
Option (Right to Purchase)	\$14.57	04/25/2019			A		9,414		(2)	04	4/25/2029	Common Stock	9,41	4	\$0	9,414		D		

Explanation of Responses:

1. Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.

Remarks:

/s/ Paul Brannelly as Attorney-

04/29/2019 In-Fact For Theodore R.

Schroeder

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer.